Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis, Eczema
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hereditary Angioedema
Interventions: KVD900 600 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Dermatitis, Contact
Interventions: T.R.U.E. Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more

Conditions: Chronic Urticaria
Interventions: Psychological Stress Intervention, General Supportive Therapy; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Temanogrel, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 85
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more

Conditions: Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 3 Years to 22 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: East Setauket, New York

Conditions: Atopic Dermatitis (Eczema)
Interventions: ARQ-151 cream 0.05%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 3 Months to 2 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more

Conditions: Atopic Dermatitis
Interventions: Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream; Drug · Device
Lead sponsor: Ceragenix Pharmaceuticals; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: San Diego, California • Portland, Oregon

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment; Drug · Other
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 10 more

Conditions: Angioedema
Interventions: Placebo, Lanadelumab; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more

Conditions: Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions: Letrozole, Bevacizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urticaria, Angioedema
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Atopic Dermatitis
Interventions: nemolizumab (CIM331), Placebo; Drug · Other
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Anniston, Alabama • San Diego, California • Miami, Florida + 13 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more

Conditions: DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions: Cyclosporine, Methylprednisolone and Prednisone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis
Interventions: Autologous Microbiome Transplant, Placebo Arm; Biological · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: KP-413 Ointment; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Clinton Twp., Michigan • Portland, Oregon • Austin, Texas + 3 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Water, Bleach, Acetic acid; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Search by objective public record fields.

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Response of Urticaria to Stress Intervention

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Remibrutinib in Real-world Clinical Practice - a US Sub-study

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Flu Vaccine Response in Patients on Biologic Therapies

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Cyclosporine Vs Steroids in DRESS

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

Validation of the Short-term Antimicrobial Action of Transplanted Bacteria

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis